香港科技大学发表的SGC皮肤再生医学文献*日前登上《Skin Pharmacology and Physiology》瑞士皮肤药理学与生理学期刊。文献内容详细阐述SGC作为崭新生物科技，显示强劲修复、再生及抗老特性。临床数据显示，SGC生物技术能让皮肤的愈合速度比正常状态下的愈合速度提升300%、皮肤弹性提高135.5%、水分流失减少35.5％、黑色素减少11.8%。
An optimized extract, named Self-Growth Colony, shows robust skin rejuvenation and anti-ageing properties: a novel technology in development of cosmetics. Chan et al. DOI: 10.1159/000513052
数据显示，施用SGC后皮肤组织中的COX2、COL1A1、MM2、TNF-a及COL2A1、COL4A1、COL5A1、COL5A2、MMP9等基因、人体天然脑神经传导体血清素、人体天然抗氧化、抗老化剂GSH谷胱甘肽、Q10、ATP等均有不同程度的增长。能促进皮肤再生(dermal regeneration)、蛋白及胶原合成(promote local protein and collagen synthesis )、内皮细胞移动（endothelial migration)、血管生成(angiogenesis)的EGF、PDGF和VEGF等生长因子都在SGC内发现，更成为SGC生物指标(bio-maker)。SGC含有的PF4(Platelet-Derived factors)和b-TG(b-thromboglobulin )这两种物质能促进血小板在血浆中的活性，从而激发a-granules产生更多生长因子，血小板活性提高是创口结痂埋口最重要因素。
数据证明，SGC在伤口修复的过程中发挥着重要作用。报告显示，利用不同时间点对HaCaT细胞进行MTT测定，能得到差别很大的检测结果。通常细胞需要24小时才能完成修复愈合；而施用SGC 8小时后，伤口修复超过90%，即比正常皮肤修复速度快300%，充分证明SGC对HaCaT细胞具有增殖作用，增殖程度比10ng / mL的VEGF更高（VEGF的融合平均百分比达到114％，而SGC的平均百分比为113-132％）。
1> 慢性及急性皮肤溃疡，例如糖尿足、老年人下肢溃疡、裖疮；
2> 改善因细胞失衡引起的敏感（俗称“激素脸”），改善荷尔蒙斑、蝴蝶斑；
3> Cox2抗炎基因提升63％，有助对抗敏感、湿疹、发炎、“网红脸”；
4> MMP2基因的提升18%，对抚平增生性肉芽及发炎红肿疤痕有针对作用，为烧、烫伤患者带来无痛治疗疤痕的希望；
5> 改善因过度整容、注射引致的轮廓生硬凹凸下坠。
、SGC美白水润 收细毛孔
透过德国C+K system (Cutometer dual MPA 580, Courage + Khazaka Electronic, Koln, Germany)医学级皮肤检测仪得到的大量临床数据显示，SGC使用者在施用SGC后，皮肤水分(skin hydration level)、含水量(water retention)、白皙度(whitening effect)、发红(erythema level)、油脂(sebum level)、光泽度(glossiness)、紧致弹性(firmness and elasticity)等方面都有非常明显的改善，特别是从单个毛孔来看都明显收细缩小，反映在皮肤上的表征为：皮肤变得光滑、细致、水润、亮白、抗氧化。
、SGC生发机理
篮子的EGF“家族”成员都能在SGC内找到，包括Transforming Growth Factor , Heparin-binding EGF (HB-EGF)和Epigen等等，它们能够修复损伤、预防脱发、促进血管生成、有助头皮毛囊细胞增殖再生。
四、SGC高度安全
SGC由一篮子活性蛋白肽组合而成，无添加防腐剂及化学剂。这些活性蛋白肽相互平衡，产生协同效应(Synergistic effect)。SGC已经成功通过加拿大SGS Ames Test及中国深圳药检所的安全检测，这两项代表国内外顶级检测项目的结果都显示：SGC不致细胞突变、无毒性。
科技量化美丽之道
【实验方法】：
1.1. protection from exogenous oxidative stressSGC sample was added to human keratinocytes (HaCaT cells). After 24 hours SGC treatment, cells were incubated with cell culture medium supplemented with tBHP, which as a reactive oxidative species (ROS) to exert oxidative stress on cells. MTT cell viability assay was then applied to determine the protective effect of SGC samples on HaCaT under oxidative stress. In short, viable HaCaT could convert yellow MTT compound into violet crystals, which can be colorimetrically quantified to reflect % viabilities.
1.2. Mushroom tyrosinase (mTyr) assayTyrosinase-catalyzed oxidation of L-DOPA is the rate determining step of melanin synthesis in human melanocytes. In the presence of mTyr, an enzyme homolog of human Tyr, L-DOPA is catalyzed into dopachrome, which can be quantified by measurement of absorbance at 492nm. SGC samples were added to reaction mixture and the reaction mixture was incubated for 20 min. The increase of tyrosinase activity implied the higher melanin synthesis with tyrosinase catalysis and the reduced A492 compared to no SGC-sample control may suggested effective skin lightening effect.1.3 Total Anti-oxidant capacity (TAC) assay
Total Anti-oxidant capacity was measured to determine the anti-oxidant power, which plays an important role in preventing the formation and scavenging of free radicals and other potentially toxic oxidizing species. In TAC assay, Trolox was used to standardize antioxidants so that antioxidants in SGC were collectively represented as Trolox equivalents. Trolox equivalent was an indication of the capability of SGC to resis oxidative damage conferred by reactive oxygen species.
AcknowledgementThis work is supported by Shenzhen Science and Technology Innovation Committee (ZDSYS201707281432317; JCYJ20170413173747440; JCYJ2018030366 6174903174), Zhongshan Municipal Bureau of Science and Technology (ZSST20SC03); Guangzhou Science and Technology Committee Research Grant (GZSTI16SC02; GZSTI17SC02); Hong Kong RGC Theme-based Research Scheme (T13-605/18-W); Hong Kong Innovation Technology Fund (UIM/340, UIM/385, ITS/500/18FP; TUYF19SC02; PD18SC01 and HMRF18SC06.
Statement of EthicsThe HKUST Human Participants Research Panel approved the study protocol. Procedures performed involving human subjects were complied with the guidelines provided by the Hong Kong University of Science and Technology Research Ethics Committee. Written informed consents were obtained from all participants.
通过香港科技大学人类参与者研究全体专家组的伦理审批。
再生医疗发展已成国际趋势
随着全球高龄人口数量的增长，罹病人口数字亦不断上升，民众医疗需求不断增加，这也是推动再生医疗市场高速发展的主要动因。SGC再生医疗技术保持研发速度快速跃进，保持显著疗效和高度安全，为急慢性皮肤问题、重度皮肤损伤等多个领域的再生治疗带来曙光。
目前，国内外大多数再生医疗公司都处于临床阶段，预计将在未来几年内陆续推出其成熟产品，其中重要的医疗厂商包括：瑞士药厂诺华集团（Novartis）、ViaCyte公司、Vericel公司、英国Tissue Regenix公司、加拿大Osiris Therapeutics公司、美国医材公司NuVasive、生物技术公司MiMedx Group、全球领先干细胞研发公司Mesoblast、私人医疗企业Acelity以及美国Cytori Therapeutics生物技术公司等。
中国台湾于2018年9月6日为“自体细胞治疗特管办法”开放六项细胞治疗技术，包含用于标准治疗无效的癌症病人与癌症末期病人的自体免疫细胞治疗，用于膝关节软骨缺损的自体软骨细胞移植，以及用于大面积烧伤及困难愈合伤口的自体脂肪干细胞移植等，也积极推动“再生医疗制剂管理条例（草案）”立法。中国香港也于2020年底依据欧盟再生医学疗法(Advanced Therapy Medicinal Products ATMP)标准完成立法。
再生医疗发展已成为不可阻挡的国际大趋势，各国之间不断竞赛，SGC贵为「中国品牌」、拥有国际认可的医学文献作为支撑、近10个国家及地区的技术专利为后盾，定能“不忘初心、牢记使命”，继续以代表中国自主研发又安全成功施用的再生医学技术，屹立于世界再生医疗研究领域的前沿位置。